Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

BUY
$30.71 - $45.71 $291,745 - $434,245
9,500 Added 74.8%
22,200 $735,000
Q4 2021

Feb 15, 2022

SELL
$37.06 - $47.11 $548,488 - $697,228
-14,800 Reduced 53.82%
12,700 $540,000
Q3 2021

Nov 16, 2021

SELL
$40.26 - $57.37 $7.38 Million - $10.5 Million
-183,300 Reduced 86.95%
27,500 $1.22 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $10.3 Million - $14.8 Million
186,800 Added 778.33%
210,800 $12 Million
Q1 2021

May 18, 2021

SELL
$70.65 - $96.76 $2.31 Million - $3.16 Million
-32,700 Reduced 57.67%
24,000 $1.8 Million
Q4 2020

Feb 17, 2021

SELL
$58.41 - $89.06 $6.72 Million - $10.3 Million
-115,100 Reduced 67.0%
56,700 $4.91 Million
Q3 2020

Nov 17, 2020

BUY
$41.13 - $62.45 $2.15 Million - $3.26 Million
52,200 Added 43.65%
171,800 $10.5 Million
Q2 2020

Aug 17, 2020

BUY
$25.95 - $43.15 $2.86 Million - $4.76 Million
110,200 Added 1172.34%
119,600 $4.97 Million
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $1.06 Million - $3.12 Million
-40,400 Reduced 81.12%
9,400 $270,000
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $2.73 Million - $7.03 Million
45,400 Added 1031.82%
49,800 $3.6 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $406,841 - $550,884
2,900 Added 193.33%
4,400 $617,000
Q2 2019

Aug 15, 2019

SELL
$157.85 - $183.09 $142,065 - $164,781
-900 Reduced 37.5%
1,500 $275,000
Q1 2019

May 16, 2019

SELL
$89.33 - $163.65 $62,531 - $114,555
-700 Reduced 22.58%
2,400 $382,000
Q4 2018

Feb 15, 2019

BUY
$81.94 - $139.71 $254,014 - $433,101
3,100 New
3,100 $297,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.